Latest Administration News

Australia United Mining reported a productive quarter at its Forsayth project with gold-silver output, but heavy rains forced a halt to mining activities. The company faces a tight cash position, relying on related party loans and potential asset sales to sustain operations.

Highfield Resources has secured a A$10 million investment from existing strategic shareholders, extending its financial runway through early 2027 while awaiting a critical Spanish Supreme Court ruling on its Goyo mining permit appeal.

TMK Energy Limited has delivered a record-breaking quarter of gas production alongside significant cost reductions, setting the stage for a pivotal year focused on commercialising its vast resource base through new partnerships.

Nexsen Limited has won a $500,000 non-dilutive grant to extend its rapid Group B Streptococcus diagnostic technology into neonatal care, opening a significant new market opportunity.

Island Pharmaceuticals has secured key regulatory milestones for its antiviral Galidesivir, including FDA confirmation of the Animal Rule pathway and Priority Review Voucher eligibility, while strengthening US biodefense ties and expanding patent protection.

Canadian Phosphate Limited reported a solid cash position of AUD 2.44 million at the end of December 2025, supported by financing activities and ongoing preparations for bulk sample mining in Canada.

Insignia Financial has responded to ASX concerns over past disclosures of performance rights, affirming shareholder approvals and outlining improved compliance measures.

Multistack International Limited has announced plans to discontinue its current business operations and is working towards disposing of its Australian subsidiary after continued losses and cash burn.

Mach7 Technologies has been notified that the Veterans Health Administration will cease its NextGen PACS program, leading to a partial stop work order and cancellation of Phase 2 of the contract. Despite this, Mach7 remains focused on its broader commercial strategy.

InvestSMART Group Limited reported a 2.2% increase in Funds Under Management to $750 million as of December 2025, supported by growth in Professionally Managed Accounts and rising subscription income. The company also extended its Employee and Director Share Plan loans and executed an on-market share buyback.

Arovella Therapeutics has filed an IND application for its lead CAR-iNKT therapy ALA-101, selected a CRO for its upcoming phase 1 trial, and secured $19.4 million in cash to fund clinical progress and pipeline expansion.

PYC Therapeutics has reported significant progress across its four RNA therapeutic programs targeting rare genetic diseases, supported by a strong cash position of $121 million at the end of 2025. Key clinical milestones and regulatory plans set the stage for upcoming trial readouts and potential market entry.